A5049069950- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Endometrial and Cervical Cancer Treatments
- Bladder and Urothelial Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Radiation Dose and Imaging
- Urologic and reproductive health conditions
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Management of metastatic bone disease
- Cervical Cancer and HPV Research
- Urinary and Genital Oncology Studies
- MRI in cancer diagnosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Urinary Bladder and Prostate Research
- Sexual function and dysfunction studies
- Advances in Oncology and Radiotherapy
- Cancer Diagnosis and Treatment
- Hormonal and reproductive studies
- Pelvic and Acetabular Injuries
- Urological Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Pelvic floor disorders treatments
Memorial Sloan Kettering Cancer Center
2016-2025
Stellar Science (United States)
2019-2024
Gynecologic Oncology Group
2019-2024
Advanced Radiation Therapy (United States)
2023-2024
Spanish Oncology Genitourinary Group
2023-2024
NYU Langone Health
2023-2024
Government of the Republic of Korea
2019
AstraZeneca (Brazil)
2019
Trillium Health Centre
2017
University Health Network
2017
Abstract BACKGROUND. The authors investigated long‐term tumor control and toxicity outcomes after high‐dose, intensity‐modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer. METHODS. Between April 1996 January 1998, 170 received 81 gray (Gy) using a 5‐field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network‐defined risk groups. Toxicity data scored Common Terminology Criteria for Adverse Events Version 3.0....
Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) in men cancer. Results Five provided evidence this update. Recommendations For low-risk who require or choose active treatment, low–dose rate (LDR) alone, EBRT and/or...
To compare tumour control and toxicity outcomes with the use of high-dose intensity-modulated radiation therapy (IMRT) alone or brachytherapy combined IMRT (combo-RT) for patients intermediate-risk prostate cancer.Between 1997 2010, 870 consecutive cancer were treated at our institution either 86.4 Gy (n = 470) combo-RT consisting 50.4 400). Brachytherapy consisted low-dose-rate permanent interstitial implantation in 260 high-dose-rate temporary 140 patients. The median (range) follow-up...
PurposeWe report the toxicity and biochemical tumor control outcome of a prospective Phase II study using high-dose-rate brachytherapy (HDR) alone as salvage therapy for recurrent disease after external beam radiotherapy (EBRT).MethodsForty-two patients with biopsy-proven recurrence were enrolled on HDR monotherapy iridium-192. Median pretreatment EBRT dose was 8100 cGy (6840–8640 cGy) median time from completion to 73 months. The protocol prescription 3200 delivered in four fractions over...
We provide a comprehensive analysis of anatomical patterns recurrence following external beam radiotherapy in patients with localized prostate cancer.This retrospective included 2,694 cancer who received definitive, dose escalated from 1991 to 2008. First sites were defined as initial clinically detected and any subsequent within 3 months. Anatomical classified local (prostate/seminal vesicles only), lymphotropic (lymph nodes only) osteotropic (bones disease confined only these respective...
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does study add? Radiation for prostate cancer can increase risk development second cancers after treatment. This highlights fact that such within pelvis do occur but are not as common previously reported. In this report we also note even among patients who develop cancers, if detected earlier, majority alive 5 years diagnosis. OBJECTIVE To incidence secondary malignancy (SM) external beam...
No AccessJournal of UrologyAdult Urology1 Sep 2014Prophylactic Sildenafil Citrate Improves Select Aspects Sexual Function in Men Treated with Radiotherapy for Prostate Cancer Michael J. Zelefsky, Daniel Shasha, Rebekah Dunn Branco, Marisa Kollmeier, Raymond E. Baser, Xin Pei, Ronald Ennis, Richard Stock, Natan Bar-Chama, and John P. Mulhall ZelefskyMichael Zelefsky Departments Radiation Oncology Urology, Memorial Sloan Kettering Center, New York, York , ShashaDaniel Shasha Department...
BACKGROUND The authors characterized the genetic landscape of chemoradiation‐treated urothelial carcinoma bladder (UCB) with objective identifying potential correlates response. METHODS Primary tumors (n = 8) or without 40) matched recurrent from 48 patients who had non‐metastatic, high‐grade UCB and received treatment primarily chemoradiation were analyzed using a next‐generation sequencing assay enriched for cancer‐related canonical DNA damage response (DDR) genes. Protein expression...
Patients with prostate cancer (PCa) treated apalutamide frequently develop rash. We aim to characterize apalutamide-related dermatological adverse events (dAEs) and management.We assessed 303 patients PCa apalutamide. DAE frequency time onset were calculated clinicopathological features management described. Associations between dAE occurrence clinical trial participation, as well abiraterone/prednisone exposure detected using logistic regression models.Seventy-one (23.4%) had all-grade...